Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2318]
News [5343]
Articles [130]
Editorials [4]
Conferences [158]
elearning [13]
Matched targeted therapy for paediatric patients with relapsed, refractory or...
Dr Yana Pikman - Dana Farber Cancer Institute, Boston, USA
Matched targeted therapy for paediatric patients with relapsed, refractory or high-risk leukemias ( Dr Yana Pikman - Dana Farber Cancer Institute, Boston, USA )
6 Dec 2018
ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline...
Dr Lorenz Trümper - Georg August University, Göttingen, Germany
ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients with T-Cell lymphomas ( Dr Lorenz Trümper - Georg August University, Göttingen, Germany )
6 Dec 2018
AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed...
Prof Marion Subklewe - University of Munich, Munich, Germany
AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed/refractory AML ( Prof Marion Subklewe - University of Munich, Munich, Germany )
6 Dec 2018
Patient treatment preferences in relapsed/refractory multiple myeloma
Dr Joseph Mikhael, Prof James Chim and Prof Evangelos Terpos
Patient treatment preferences in relapsed/refractory multiple myeloma ( Dr Joseph Mikhael, Prof James Chim and Prof Evangelos Terpos )
3 Dec 2018
Landscape change with oral proteasome maintenance in multiple myeloma patients
Prof Maria-Victoria Mateos, Prof Wee Joo Chng, Prof Meral Beksac and Dr Sagar...
Landscape change with oral proteasome maintenance in multiple myeloma patients ( Prof Maria-Victoria Mateos, Prof Wee Joo Chng, Prof Meral Beksac and Dr Sagar Lonial )
3 Dec 2018
The importance of NF-kB pathway in myeloma
Dr Nizar Bahlis - University of Calgary, Calgary, Canada
The importance of NF-kB pathway in myeloma ( Dr Nizar Bahlis - University of Calgary, Calgary, Canada )
3 Dec 2018
Multiple myeloma highlights and more from ASH 2018
Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France
Multiple myeloma highlights and more from ASH 2018 ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )
3 Dec 2018
Results of the Beat AML umbrella study for previously untreated acute myeloid...
Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA
Results of the Beat AML umbrella study for previously untreated acute myeloid leukaemia ( Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA )
3 Dec 2018
ASH 2018: Expert overview of the latest in CLL, ALL and AML
Prof Robin Foa - University of Rome, Rome, Italy
ASH 2018: Expert overview of the latest in CLL, ALL and AML ( Prof Robin Foa - University of Rome, Rome, Italy )
3 Dec 2018
ECHELON-2: a large peripheral T-cell lymphoma trial
Dr Owen O'Connor - Columbia University Medical Centre, New York, USA
ECHELON-2: a large peripheral T-cell lymphoma trial ( Dr Owen O'Connor - Columbia University Medical Centre, New York, USA )
2 Dec 2018
ACT-1: Addition of alemtuzumab to a CHOP backbone for young patients with T...
Dr Owen O'Connor - Columbia University Medical Centre, New York, USA
ACT-1: Addition of alemtuzumab to a CHOP backbone for young patients with T-cell lymphoma ( Dr Owen O'Connor - Columbia University Medical Centre, New York, USA )
2 Dec 2018
Reduction of chemotherapy cycles for diffuse large B-cell lymphoma
Dr Viola Pöschel - Saarland University Medical School, Homburg, Germany
Reduction of chemotherapy cycles for diffuse large B-cell lymphoma ( Dr Viola Pöschel - Saarland University Medical School, Homburg, Germany )
1 Dec 2018

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation